No price history available.
Key financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CHFm | 823 | 948 | 1,151 | 1,152 | 1,108 | 1,101 | N/A | N/A |
| Operating profit | CHFm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CHFm | -346 | 194 | 105 | 67 | 31 | 81 | N/A | N/A |
| EPS reported | CHF | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CHF | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CHF | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CHF | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CHFm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CHFm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CHFm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CHF | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CHF | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Dätwyler Holding AG, established in 1915 and headquartered in Altdorf, Switzerland, operates as a subsidiary of Pema Holding AG. The company specializes in the global manufacturing and distribution of elastomer components for a variety of sectors, including healthcare, mobility, oil and gas, and food and beverage, with its reach extending across Europe, North America, South America, and Asia. Dätwyler is organized into two core divisions: Healthcare Solutions and Industrial Solutions. The Healthcare Solutions segment provides critical rubber components for medical applications such as prefilled syringes, injection pens, vial closures for injectable pharmaceuticals, blood collection systems, IV administration sets, disposable syringes, and diagnostic and medical devices. Meanwhile, the Industrial Solutions segment offers a diverse portfolio of products, including electromobility solutions, active assistance and safety systems, brake components, fuel and engine management systems, exhaust gas aftertreatment, and sealing components for upstream systems, power tools, and the water and process industries.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Dätwyler Holding AG, established in 1915 and headquartered in Altdorf, Switzerland, operates as a subsidiary of Pema Holding AG. The company specializes in the global manufacturing and distribution of elastomer components for a variety of sectors, including healthcare, mobility, oil and gas, and food and beverage, with its reach extending across Europe, North America, South America, and Asia. Dätwyler is organized into two core divisions: Healthcare Solutions and Industrial Solutions. The Healthcare Solutions segment provides critical rubber components for medical applications such as prefilled syringes, injection pens, vial closures for injectable pharmaceuticals, blood collection systems, IV administration sets, disposable syringes, and diagnostic and medical devices. Meanwhile, the Industrial Solutions segment offers a diverse portfolio of products, including electromobility solutions, active assistance and safety systems, brake components, fuel and engine management systems, exhaust gas aftertreatment, and sealing components for upstream systems, power tools, and the water and process industries.